Cerebrolysin vs P21
Comparison of Cerebrolysin (Moderate evidence) and P21 (Very Low evidence).
Last updated: February 12, 2026
Cerebrolysin
P21
Overview
Cerebrolysin and P21 are both studied in the peptide research space.
Cerebrolysin: A porcine brain-derived peptide mixture approved in over 50 countries (Austria, Russia, China, Germany) for stroke, dementia, and traumatic brain injury.
P21: A hexapeptide (Ac-DGGLAG-NH2) derived from ciliary neurotrophic factor (CNTF) that is claimed to mimic BDNF effects and promote neurogenesis.
Evidence Comparison
| Aspect | Cerebrolysin | P21 |
|---|---|---|
| Evidence Level | Moderate | Very Low |
| Human Studies | 22 | 0 |
| Preclinical Studies | 10 | 15 |
| Total Sources | 32 | 15 |
Key Differences
| Aspect | Cerebrolysin | P21 |
|---|---|---|
| Category | Cognitive | Cognitive |
| Evidence Strength | Moderate | Very Low |
| Total Sources | 32 | 15 |
| Human Studies | 22 | 0 |
Summary
- Cerebrolysin: Moderate evidence with 32 total sources (22 human)
- P21: Very Low evidence with 15 total sources (0 human)
This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.